Search results for "mycoses"

showing 10 items of 351 documents

Accuracy of two plasma antibody tests and faecal antigen test for non-invasive detection of H. pylori in middle-aged Caucasian general population sam…

2018

The aim of the study was to assess the accuracy of two plasma Helicobacter pylori (H. pylori) antibody test-systems and a stool antigen test (SAT) system in a general population sample in Latvia.Blood and faecal samples were analysed in healthy individuals (40-64 years), referred for upper gastrointestinal endoscopy according to pilot study protocol within a population-based study investigating gastric cancer prevention strategies (GISTAR pilot study). Antibodies to H. pylori were assessed in plasma by latex-agglutination test and enzyme-linked immunosorbent assay (ELISA). H. pylori antigen in faecal samples was detected by a monoclonal enzyme immunoassay-based SAT. Histological assessment …

AdultMalePopulation sampleEnzyme-Linked Immunosorbent AssayPilot ProjectsSensitivity and SpecificityHelicobacter Infections03 medical and health sciencesFeces0302 clinical medicineMedicineHumansSerologic TestsAntigens BacterialbiologyHelicobacter pyloribusiness.industryNon invasiveGastroenterologyHelicobacter pyloriMiddle Agedbacterial infections and mycosesbiology.organism_classificationAntigen testAntibodies BacterialLatex fixation testROC Curve030220 oncology & carcinogenesisImmunologybiology.proteinStool antigen030211 gastroenterology & hepatologyFemaleFranceAntibodybusinessScandinavian journal of gastroenterology
researchProduct

Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

2007

Invasive fungal infections are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation.In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy. The primary end point was the incidence of proven or probable invasive fungal infections from randomization to day 112 of the fixed treatment period of the study.Of a total of 600 patients, 301 were assigned to posaconazole and 299 to fluconazole. At the end of the fixed 112-day treatment period, posaconazole wa…

AdultMalePosaconazolemedicine.medical_specialtyAntifungal AgentsAdolescentmedicine.medical_treatmentGraft vs Host DiseaseKaplan-Meier EstimateHematopoietic stem cell transplantationOpportunistic InfectionsAspergillosisDouble-Blind MethodRisk FactorsInternal medicinemedicineClinical endpointAspergillosisHumansFluconazoleAgedbusiness.industryIncidence (epidemiology)Hematopoietic Stem Cell TransplantationGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryTransplantationGraft-versus-host diseaseMycosesFemalebusinessFluconazolemedicine.drugNew England Journal of Medicine
researchProduct

vacA genotypes in oral cavity and Helicobacter pylori seropositivity among adults without dyspepsia.

2010

Objective: The aims of this research were to determine the prevalence of Helicobacter pylori and its vacA genotypes in oral cavity in persons without dyspepsia and to establish the association between the presence of H. pylori in oral cavity and oral hygiene. The seroprevalence of anti-H. pylori antibodies and its associated factors were analyzed too. Study design: For the study, 200 adults without dyspepsia symptoms were selected. Dental plaque and saliva samples from each subject were obtained. H. pylori detection in oral samples was carried out by polymerase chain reaction (PCR) and for vacA genotyping a semi-nested and nested PCR was used. The enzyme-linked immunosorbent assay (ELISA) w…

AdultMaleSalivaGenotypeDental plaqueAsymptomaticOral hygieneHelicobacter InfectionsYoung AdultBacterial ProteinsSeroepidemiologic StudiesmedicineSeroprevalenceHumansGeneral DentistryGenotypingMouthbiologyHelicobacter pyloribusiness.industryHelicobacter pyloriMiddle Agedmedicine.diseasebiology.organism_classificationbacterial infections and mycoses:CIENCIAS MÉDICAS [UNESCO]Antibodies BacterialOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASImmunologySurgeryFemalemedicine.symptombusinessNested polymerase chain reactionMedicina oral, patologia oral y cirugia bucal
researchProduct

Exogenous and endogenous provocation of psoriasis. A contribution to the Koebner phenomenon.

1974

Previous literature reports as well as own investigations concerning exogenously and endogenously induced Koebner-reactions in psoriatics are presented. The time interval between irritation and the Koebner-reaction is emphasized. It is proposed, that the intensity of the psoriatic reaction is mediated by circulating DHEA-deficiency. Hypothetical models are presented which allow to explain the different developmental rates of psoriatic lesions in relation to the type of irritation, the area affected and the subsequent proliferative responses.

AdultMaleTime FactorsAdolescentProvocation testKoebner phenomenonEndogenyDermatologymedicine.disease_causeInfectionsFoodborne DiseasesPostoperative ComplicationsPsoriasisPhysical StimulationSkin ManifestationsInfluenza HumanCyclic AMPMedicinePsychological stressHumansPsoriasisChildSkinSkin manifestationsbusiness.industryVaccinationGeneral MedicineDehydroepiandrosteroneSyndromeMiddle Agedmedicine.diseaseStimulation ChemicalMycosesImmunologyWounds and InjuriesFemaleIrritationbusinessStress PsychologicalArchiv fur dermatologische Forschung
researchProduct

Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease

2015

Cytotoxic molecules such as granulysin, perforin and granzymes produced by cytolytic T cells directly contribute to immune defense against tuberculosis (TB). In search for novel TB biomarkers, we have evaluated the levels of granzyme A in plasma obtained from QuantiFERON-TB Gold In tube (QFT-IT) assays from patients with active TB disease and subjects with latent TB infection (LTBI).Granzyme A serum levels in TB patients were significantly lower than values found in LTBI subjects even after subtraction of the unstimulated levels from the antigen-stimulated responses. The receiver operator characteristics (ROC) curve analysis comparing TB patients and LTBI groups, showed that at a cut-off va…

AdultMaleTuberculosisTuberculosiImmunologyDisease; Granzyme A; IFN-γ; IGRA tests; Infection; Tuberculosis; Adult; Antigens Bacterial; Biomarkers; Case-Control Studies; Female; Granzymes; Humans; Interferon-gamma; Latent Tuberculosis; Male; Middle Aged; Mycobacterium tuberculosis; ROC Curve; Tuberculosis; Young Adult; Immunology and Allergy; ImmunologyMycobacterium tuberculosiIFN-γGranzymesMycobacterium tuberculosisIGRA testInterferon-gammaYoung AdultLatent TuberculosismedicineHumansTuberculosisImmunology and AllergyDiseaseGranulysinGranzymeAntigens BacterialLatent TuberculosibiologyLatent tuberculosisGranzyme AMycobacterium tuberculosisBiomarkerMiddle Agedbacterial infections and mycosesmedicine.diseasebiology.organism_classificationROC CurvePerforinGranzymeCase-Control StudiesImmunologybiology.proteinGranzyme ABiomarker (medicine)FemaleInfectionCase-Control StudieBiomarkersHuman
researchProduct

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

2011

Antifungal prophylaxis for allogeneic haematopoietic stem-cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) and be well tolerated. This prospective, randomized, open-label, multicentre study compared the efficacy and safety of voriconazole (234 patients) versus itraconazole (255 patients) in alloHCT recipients. The primary composite endpoint, success of prophylaxis, incorporated ability to tolerate study drug for ≥100 d (with ≤14 d interruption) with survival to day 180 without proven/probable IFI. Success of prophylaxis was significantly higher with voriconazole than itraconazole (48·7% vs. 33·2%, P 10%) treatment-related adverse events were vom…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleazolesstem-cell transplantPharmacologyBiologyAspergillosisGastroenterologyYoung AdultInternal medicineAmphotericin BmedicineHumansTransplantation Homologousyeast infectionsProspective StudiesChildAdverse effectAgedVoriconazoleHaematological MalignancyHematopoietic Stem Cell TransplantationHematologyMiddle AgedTriazolesmedicine.diseaseinvasive fungal diseaseTransplantationPyrimidinesMycosesmould infectionsFemaleVoriconazoleLiver functionItraconazoleFluconazolemedicine.drugBritish Journal of Haematology
researchProduct

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

2007

Summary Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentLipoproteinsAmphotericin B/ therapeutic useMicrobial Sensitivity TestsLipoproteins/ therapeutic usePeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BPeptides Cyclic/ therapeutic usemedicineHumansAdverse effectMycosisFungemiaCandidiasis/complications/ drug therapy/microbiologyAPACHEAgedddc:616Aged 80 and overVoriconazolebusiness.industryAntifungal Agents/ therapeutic useCandidiasisMicafunginGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseApacheSurgeryTreatment OutcomechemistryMicafunginFemaleCaspofunginbusinessFluconazolemedicine.drugThe Lancet
researchProduct

Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dos…

2015

ABSTRACT Isavuconazole is a novel broad-spectrum triazole antifungal agent. This open-label dose escalation study assessed the safety and pharmacokinetics of intravenous isavuconazole prophylaxis in patients with acute myeloid leukemia who had undergone chemotherapy and had preexisting/expected neutropenia. Twenty-four patients were enrolled, and 20 patients completed the study. The patients in the low-dose cohort ( n = 11) received isavuconazole loading doses on day 1 (400/200/200 mg, 6 h apart) and day 2 (200/200 mg, 12 h apart), followed by once-daily maintenance dosing (200 mg) on days 3 to 28. The loading and maintenance doses were doubled in the high-dose cohort ( n = 12). The mean ± …

AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaPyridinesClinical TherapeuticsNeutropeniaCohort StudiesPharmacokineticsInternal medicineNitrilesHumansMedicinePharmacology (medical)DosingAdverse effectAgedImmunosuppression TherapyPharmacologyDose-Response Relationship Drugbusiness.industryMiddle AgedTriazolesmedicine.diseaseIsavuconazoniumSurgeryLeukemia Myeloid AcuteInfectious DiseasesMycosesTolerabilityCohortFemalePatient Safetybusinessmedicine.drugCohort studyAntimicrobial Agents and Chemotherapy
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week

2009

<i>Background:</i> Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is characterized by recurrent edema attacks in various organs. The objective of the present study was to assess the efficacy and safety of weekly long-term replacement treatment with one or more injections of plasma-derived C1-INH concentrate per week (WLTC) in patients with HAE-C1-INH. <i>Methods:</i> Nineteen patients with HAE-C1-INH underwent WLTC for 9 years on average. The benefits and risks were determined based on regular recording by the patients of the severity and number of attacks at the beginning and the end of the study. <i>Results:</i> All patients reported …

AdultMalemedicine.medical_specialtyLong term treatmentC1 inhibitor deficiencyImmunologyBradykininGastroenterologyDrug Administration ScheduleC1-inhibitorEdemaInternal medicineHumansImmunology and AllergyMedicineProspective Studiesskin and connective tissue diseasesBradykinin Receptor AntagonistsC1 esterase inhibitor deficiencyAgedbiologyAngioedemabusiness.industryAngioedemas HereditaryGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSurgeryHereditary angioedemaImmunologybiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinInternational Archives of Allergy and Immunology
researchProduct